PATENT CLAIM ANALYSIS

Application Number: 15868688
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["514", "001900"]

Abstract:
The invention is directed to a pharmaceutical composition containing at least one FGF-21 (fibroblast growth factor 21) compound, at least one GLP-1R (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one DPP-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas.

Claim (Index 29):
A method of treating atherosclerosis in a patient, the method comprising administering to a patient in need thereof a therapeutically effective amount of a combination comprising at least one fibroblast growth factor 21 (FGF-21) compound and at least one glucagon-like peptide-1 receptor (GLP-1R) agonist.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 86.0
- Lexical Diversity: 1.42857
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15248712', '15851963', '13626207', '14630206', '14987338']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7598042288133549
- 35 USC 102 Novelty (BERT): 0.5026465404977555
- Combined Prediction Score: 0.734088459981795
- Mean Citation Score: 249.016272
- Max Citation Score: 256.4285
- Similarity Product: 181.9194716114997

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test